1-5 of 5
Urban Emmenegger
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Randomized Phase II Study of Durvalumab with or without Tremelimumab in Patients with Metastatic Castration-Resistant Prostate Cancer

Eric Winquist, Sebastien J. Hotte, Kim Chi, Srikala Sridhar, Susan Ellard, Michael Ong, Nayyer Iqbal, Muhammad Salim, Urban Emmenegger, Joel R. Gingerich, Aly-Khan Lalani, Pierre Major, Christian Kollmannsberger, Steven Yip, Aaron Hansen, Daygen Finch, Christina Canil, James Hutchenreuther, Francisco Vera-Badillo, Martin Smoragiewicz, Michael Cabanero, Ming-Sound Tsao, Elie Ritch, Alexander W. Wyatt, Lesley Seymour
Journal: Clinical Cancer Research
Clin Cancer Res OF1–OF11.
https://doi.org/10.1158/1078-0432.CCR-24-1612
Published: 03 December 2024
View article titled, Randomized Phase II Study of Durvalumab with or without Tremelimumab in Patients with Metastatic Castration-Resistant Prostate Cancer
Open the PDF for Randomized Phase II Study of Durvalumab with or without Tremelimumab in Patients with Metastatic Castration-Resistant Prostate Cancer in another window
Includes: Supplementary data
Journal Articles

Comparative Impact of Trastuzumab and Cyclophosphamide on HER-2–Positive Human Breast Cancer Xenografts

Giulio Francia, Shan Man, Chyan-Jang Lee, Christina R. Lee, Ping Xu, Miriam E. Mossoba, Urban Emmenegger, Jeffrey A. Medin, Robert S. Kerbel
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (20): 6358–6366.
https://doi.org/10.1158/1078-0432.CCR-09-0931
Published: 14 October 2009
View article titled, Comparative Impact of Trastuzumab and Cyclophosphamide on HER-2–Positive Human Breast Cancer Xenografts
Open the PDF for Comparative Impact of Trastuzumab and Cyclophosphamide on HER-2–Positive Human Breast Cancer Xenografts in another window
Includes: Supplementary data
Journal Articles

Strategies for Delaying or Treating In vivo Acquired Resistance to Trastuzumab in Human Breast Cancer Xenografts

Jeanne M. du Manoir, Giulio Francia, Shan Man, Miriam Mossoba, Jeffrey A. Medin, Alicia Viloria-Petit, Daniel J. Hicklin, Urban Emmenegger, Robert S. Kerbel
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (3): 904–916.
https://doi.org/10.1158/1078-0432.CCR-05-1109
Published: 07 February 2006
View article titled, Strategies for Delaying or Treating <em>In vivo</em> Acquired Resistance to Trastuzumab in Human Breast Cancer Xenografts
Open the PDF for Strategies for Delaying or Treating <em>In vivo</em> Acquired Resistance to Trastuzumab in Human Breast Cancer Xenografts in another window
Journal Articles

A Dynamic De-Escalating Dosing Strategy to Determine the Optimal Biological Dose for Antiangiogenic Drugs

Urban Emmenegger, Robert S. Kerbel
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (21): 7589–7592.
https://doi.org/10.1158/1078-0432.CCR-05-1387
Published: 08 November 2005
View article titled, A Dynamic De-Escalating Dosing Strategy to Determine the Optimal Biological Dose for Antiangiogenic Drugs
Open the PDF for A Dynamic De-Escalating Dosing Strategy to Determine the Optimal Biological Dose for Antiangiogenic Drugs in another window
Journal Articles

Metronomic Low-Dose Chemotherapy Boosts CD95-Dependent Antiangiogenic Effect of the Thrombospondin Peptide ABT-510: A Complementation Antiangiogenic Strategy

Ronald Yap, Dorina Veliceasa, Urban Emmenegger, Robert S. Kerbel, Laura M. McKay, Jack Henkin, Olga V. Volpert
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (18): 6678–6685.
https://doi.org/10.1158/1078-0432.CCR-05-0621
Published: 15 September 2005
View article titled, Metronomic Low-Dose Chemotherapy Boosts CD95-Dependent Antiangiogenic Effect of the Thrombospondin Peptide ABT-510: A Complementation Antiangiogenic Strategy
Open the PDF for Metronomic Low-Dose Chemotherapy Boosts CD95-Dependent Antiangiogenic Effect of the Thrombospondin Peptide ABT-510: A Complementation Antiangiogenic Strategy in another window